Navigation Links
Omni Bio Pharmaceutical Intends to Expand Type 1 Diabetes Trial to 50 Patients
Date:2/28/2011

DENVER, Feb. 28, 2011 /PRNewswire/ -- (OTC Bulletin Board: OMBP) Omni Bio Pharmaceutical, Inc. ("Omni Bio"), an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential, has committed to expand its Phase I/II human clinical trial in recently diagnosed Type 1 diabetes patients from 15 patients to 50.

The expansion of the trial population has been approved by the FDA.  The trial, which is currently underway at the Barbara Davis Center for Childhood Diabetes ("BDC") at the University of Colorado-Denver Anschutz Medical Campus, has seen improvement in the condition of the first enrolled patients.  Based on observations of the first enrolled patients at BDC, Omni Bio intends to expand the patient enrollment to 50 patients, which may involve obtaining a second trial site.

Dr. James Crapo Omni Bio's Chief Executive Officer stated, "We are currently engaged in discussions related to expanding our Type 1 diabetes trial from the initially targeted 15 patients to a total of 50 patients.  The expansion of the trial will cause a substantially greater amount of statistically relevant scientific data to be generated, allowing us to better assess our next steps in pursuing this indication."

The expansion of the clinical trial would result in an increase of clinical trial service costs of approximately $2 million, excluding drug costs, and would require Omni Bio to raise additional financing before the expansion of the trial can begin.  There is no assurance that Omni Bio will be able to raise additional capital to fund the expansion of the clinical trial on acceptable terms or at all.

Omni Bio is also pleased to announce that it has received letters of intent for human clinical trials at a number of institutions in the United States and Europe, contingent
'/>"/>

SOURCE Omni Bio Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   Regulus Therapeutics Inc ... company leading the discovery and development of innovative ... its ATHENA natural history of disease study in ... disease with no approved therapy. The ATHENA study ... renal function markers such as Glomerular Filtration Rate ...
(Date:9/18/2014)... and ROCKVILLE, Md. , ... SPPI ), a biotechnology company with fully integrated ... in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ...
(Date:9/18/2014)... Sept. 18, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that the Company,s ... Geert Cauwenbergh , will present at the ... on Wednesday, September 24, 2014 at 11:20 ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... 2011 On Sunday, August 21, veterinary cardiologists are ... the Mobile Dog Heart Health Tour will stop with ... examinations at Peters Park Dog Run. (Photo: ... free heart health screenings, veterinarians will be available to ...
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... it has finalized a previously disclosed Equipment Financing ... $10 million in available funding. This agreement will ... finance the automated assembly line now manufacturing the ...
Cached Medicine Technology:Free Dog Heart Health Screenings Available August 21 in Boston 2Unilife Signs $10 Million Equipment Financing Agreement 2Unilife Signs $10 Million Equipment Financing Agreement 3Unilife Signs $10 Million Equipment Financing Agreement 4
(Date:9/18/2014)... that elderly men should not be routinely screened for ... a new study led by researchers at Henry Ford ... in JAMA Internal Medicine , focused on the ... for prostate cancer., "We found that the effect of ... men in particular has been minimal at best," says ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 ChopChop ... Bill Yosses and Yonah Kalikow, 10-year-old Massachusetts’s winner of the ... twist on hummus, the classic Middle Eastern bean dip. Watch ... stage how kids can create their own healthy dips at ... at the third annual Let’s Talk About Food Festival ...
(Date:9/18/2014)... Technology Association of Georgia in collaboration with TAG ... Savvy Awards this week at a special ceremony held ... Downtown Atlanta. The event celebrates Georgia’s best and brightest ... with the 2014 TAG Social Savvy People’s Choice Award ... 6 other award categories: , ,     UPS ...
(Date:9/18/2014)... 18, 2014 Once again, Hickman’s Family ... restaurants around the Valley to celebrate PJs & Eggs. ... Egg Day”: Friday, October 10, 2014. The “breakfast for ... to benefit Arizona’s Children Association (AzCA) foster care programs ... at each participating restaurant on October 10 are invited ...
(Date:9/18/2014)... cancer-hampering molecules show promise in slowing the progression ... often linked to asbestos. Scientists from Case Western ... demonstrate that application of curcumin, a derivative of ... of a protein inhibitor known to combat the ... the Aug. 14 online edition Clinical Cancer ...
Breaking Medicine News(10 mins):Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 3Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3Health News:October 10th Is 6th Annual PJs & Eggs: Hickman’s Family Farms and Breakfast Restaurants Partner to Benefit Arizona Foster Children 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 3
... The most common form of thalassaemia disease may ... ,Hemoglobin E ? thalassaemia—the commonest form of ... without transfusion in many patients, suggests a research ... The Lancet. The authors state that the finding ...
... of researchers at Vienna University have said they are ... it will be effective against lung cancer//. , ... much more research was still needed before the new ... statement Tuesday. , ,"In fact it's a paradox," ...
... to complex problems lies at hand but that is the ... new anti obesity drug//. A weight control protein with a ... content may yield new approaches for treating obesity and type ... particular variants of the protein SH2-B might underlie obesity in ...
... found a new protein which may be responsible for the ... is known as MSF protein is produced in high quantity ... produced may be responsible for the severity of disease progression. ... protein, the scientists are looking into the properties of these ...
... vulnerable to suffer from the dreaded disease of multiple ... risk//. ,According to the most complete genetic study ... from Vanderbilt University in Nashville, Tennessee at the 130th ... Diego, a cluster of genes on chromosome six is ...
... research report published in the latest issue of Archives ... ready to deal with the threat of bio-terrorism that ... ,More than one-half of 631 physicians tested were ... likely to be used by bio-terrorists. However, test scores ...
Cached Medicine News:Health News:Flu Vaccine Can Be Used To Treat Lung Cancer 2Health News:An Answer To Obesity: Weight Control Protein 2
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Curette, 145 mm...
Bone Currettes...
Medicine Products: